Annuncio pubblicitario
Italia markets close in 6 hours 16 minutes

  • FTSE MIB

    33.766,66
    +20,00 (+0,06%)
     

  • Dow Jones

    37.903,29
    +87,37 (+0,23%)
     

  • Nasdaq

    15.605,48
    -52,34 (-0,33%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • Petrolio

    79,65
    +0,65 (+0,82%)
     

  • Bitcoin EUR

    53.940,02
    +339,83 (+0,63%)
     

  • CMC Crypto 200

    1.267,79
    -2,95 (-0,23%)
     

  • Oro

    2.313,40
    +2,40 (+0,10%)
     

  • EUR/USD

    1,0711
    -0,0007 (-0,06%)
     

  • S&P 500

    5.018,39
    -17,30 (-0,34%)
     

  • HANG SENG

    18.207,13
    +444,10 (+2,50%)
     

  • Euro Stoxx 50

    4.890,44
    -30,78 (-0,63%)
     

  • EUR/GBP

    0,8548
    -0,0004 (-0,05%)
     

  • EUR/CHF

    0,9769
    -0,0051 (-0,52%)
     

  • EUR/CAD

    1,4684
    -0,0022 (-0,15%)
     

Nestlé divests its Palforzia business

Nestlé S.A.
·1 minuto per la lettura
Nestlé S.A.
Nestlé S.A.

[Ad hoc announcement pursuant to Art. 53 LR]

This press release is also available in Français (pdf) and Deutsch (pdf)

.............


Vevey, September 4, 2023


Nestlé divests its Palforzia business


Nestlé announced today that is has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing.

This agreement follows Nestlé's announcement last year that it would conduct a strategic review of Palforzia. Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer.

ANNUNCIO PUBBLICITARIO

"We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world," said Greg Behar, CEO of Nestlé Health Science. "At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers."

There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.

 

Contacts:

Media:
Christoph Meier  Tel.: +41 21 924 2200
mediarelations@nestle.com

Investors:
Luca Borlini  Tel.: +41 21 924 3509
ir@nestle.com